TrialNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2023

The D-amino acid oxidase inhibitor luvadaxistat improves mismatch negativity in patients with schizophrenia in a randomized trial.

Patricio O'Donnell et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.